CJC-1295 Switching Protocols: How to Transition To and From Other Growth Hormone Secretagogues

What CJC-1295 Is and How It Works

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH) that has been chemically modified at positions 2, 8, 15, and 27 of the native GRF 1-29 sequence to resist dipeptidyl peptidase IV (DPP-IV) cleavage. The drug-affinity complex (DAC) version adds a lysine-maleimide linker that covalently binds circulating albumin, extending plasma half-life from roughly 30 minutes (no-DAC) to approximately 6 to 8 days. [1]

Receptor Binding and GH Pulse Amplification

CJC-1295 binds the pituitary GHRH receptor (GHRHR), a Gs-protein-coupled receptor. Activation raises intracellular cAMP, which opens voltage-gated calcium channels and triggers GH exocytosis. Because it does not occupy the ghrelin/GHS-R1a receptor, it works through a mechanistically distinct pathway from growth hormone releasing peptides (GHRPs) such as ipamorelin or hexarelin.

The result is an amplification of existing GH pulses rather than creation of entirely new ones. Somatostatin tone still modulates the ceiling of each pulse, which is one reason the DAC variant's "GH bleed" profile looks different from the sharp spikes produced by ipamorelin. [2]

The DAC vs. No-DAC Distinction Matters for Switching

A point that confuses many prescribers: "CJC-1295" in the literature almost always refers to the DAC version. "Modified GRF 1-29" or "mod-GRF 1-29" refers to the no-DAC version. The two compounds share the same core sequence but have entirely different pharmacokinetic profiles, and that difference drives every switching decision covered in this article.

Teichman et al. (J Clin Endocrinol Metab, 2006, N=65) demonstrated that a single 2 mg subcutaneous dose of CJC-1295 (DAC) produced a 2- to 10-fold increase in mean GH concentrations and a 1.5- to 3-fold increase in IGF-1, with effects persisting for 6 days at lower doses and for the full 8-day measurement window at 2 mg. [1] No comparable sustained IGF-1 elevation has been documented with no-DAC modified GRF after a single administration.

Pharmacokinetics Summary Across the Drug Class

Before any switching decision, a prescriber must map each agent's effective duration against the patient's current IGF-1 trajectory.

| Agent | Mechanism | Effective Duration | Typical Frequency | |---|---|---|---| | CJC-1295 (DAC) | GHRH-R agonist, albumin-bound | ~6 to 8 days | Once weekly | | Mod-GRF 1-29 (no-DAC) | GHRH-R agonist | ~30 min | 1 to 3x daily | | Sermorelin | GHRH-R agonist, native GRF 1-29 | ~10 to 20 min | Daily (bedtime) | | Tesamorelin | GHRH-R agonist, trans-3-hex modified | ~26 min | Daily (500 mcg) | | Ipamorelin | GHS-R1a agonist (GHRP) | ~2 hours | 1 to 3x daily | | MK-677 (ibutamoren) | GHS-R1a agonist, oral | ~24 hours | Once daily |

Sources: FDA prescribing information for tesamorelin (Egrifta); [3] published PK modeling for sermorelin; [4] receptor pharmacology review by Popovic et al. [2]

Why Clinicians Switch Patients Between GH Secretagogues

Loss of Response to a GHRH Analog

Receptor downregulation is the most common reason. A 2019 review in Growth Hormone and IGF Research documented tachyphylaxis to continuous GHRH analog infusion within 4 to 8 weeks in animal models, though pulsatile subcutaneous dosing appears to delay this considerably. [5] If IGF-1 plateaus despite confirmed adherence and proper injection technique, a class switch may restore sensitivity.

Tolerability Issues

The DAC variant's prolonged GH bleed can worsen fluid retention, carpal tunnel symptoms, or fasting glucose in susceptible patients. Switching to a shorter-acting agent such as sermorelin or mod-GRF 1-29 allows IGF-1 to return closer to baseline between doses, which may relieve these side effects.

Protocol Optimization

Some patients are switched onto CJC-1295 (DAC) from mod-GRF 1-29 or sermorelin specifically because once-weekly dosing improves adherence. The FDA-approved comparator here is tesamorelin, where a once-daily subcutaneous injection reduced visceral adipose tissue by 15.2% at 26 weeks in the AXIS-I trial (N=412, P<0.001). [3] A prescriber may want similar visceral-fat effects without the daily injection burden.

Transition Off a GHRH Analog Entirely

Patients discontinuing peptide therapy before surgery, during pregnancy planning, or after reaching IGF-1 optimization targets need a structured taper rather than an abrupt stop.

Switching From CJC-1295 (DAC) to Another Agent

To Mod-GRF 1-29 / Ipamorelin (Daily Protocol)

This is the most common switch. The rationale is usually to tighten IGF-1 control or to add a GHRP-mediated pulse on top of a GHRH backbone.

Recommended approach:

1. Administer the final CJC-1295 (DAC) dose on day 0.
2. Wait 14 days. This allows plasma levels to decline by approximately 2 half-lives, reducing residual GHRH-R occupancy enough to avoid overshooting IGF-1 when the daily protocol begins.
3. Start mod-GRF 1-29 (100 to 300 mcg) combined with ipamorelin (100 to 300 mcg) subcutaneously 30 to 60 minutes before bedtime on day 14.
4. Check IGF-1 at week 4 of the new protocol and titrate dose upward in 50 mcg increments only if IGF-1 remains below the lower third of the age-adjusted reference range.

There is no published randomized trial directly comparing these two protocols head-to-head. The washout guidance above is derived from first-principles PK (2 x 8-day half-life = 16 days to approximately 25% residual) and is consistent with the compounding pharmacology literature reviewed by Walker. [6]

To Sermorelin

Sermorelin's half-life is roughly 10 to 20 minutes, so receptor competition with residual CJC-1295 is the primary concern during transition, not the other way around.

Use the same 14-day washout. Start sermorelin at 200 mcg subcutaneously at bedtime. Because sermorelin stimulates GH release only during the natural nocturnal surge, morning IGF-1 draws may underestimate the pharmacodynamic effect for the first 2 to 4 weeks.

The FDA accepted sermorelin (Geref) for pediatric GH deficiency based on IGF-1 normalization as a surrogate endpoint. [4] That regulatory precedent informs the monitoring approach in adults: IGF-1 is the primary efficacy marker, not fasting GH.

To Tesamorelin

Tesamorelin (Egrifta) is the only FDA-approved GHRH analog currently on the market. It carries a specific indication for HIV-associated lipodystrophy at 2 mg subcutaneous daily. [3]

Switching a patient from CJC-1295 (DAC) to tesamorelin requires the same 14-day washout for PK reasons. Dosing must match the FDA-approved regimen (2 mg daily, not 500 mcg) for the approved indication. Off-label use at lower doses for general GH optimization is outside the current label.

IGF-1 tends to rise faster with tesamorelin than with sermorelin because of tesamorelin's modified trans-3-hexenoic acid group, which confers greater DPP-IV resistance than native sermorelin without the albumin-binding of the DAC moiety. [3]

To MK-677 (Ibutamoren)

MK-677 is an oral, non-peptide GHS-R1a agonist. It does not bind GHRHR at all, so mechanistic overlap with CJC-1295 is minimal. Despite that, both agents raise IGF-1, and stacking them without a washout risks supraphysiologic IGF-1 levels.

The recommended washout is still 14 days from the last CJC-1295 (DAC) dose. Start MK-677 at 10 mg orally at bedtime. Murphy et al. (J Clin Endocrinol Metab, 1998, N=32) showed that 2-year continuous MK-677 at 25 mg/day increased IGF-1 by 39.9% in healthy older adults. [7] Fasting glucose elevation (mean +0.3 mmol/L in that cohort) means glucose monitoring is warranted at weeks 4 and 12 of the new protocol.

Switching TO CJC-1295 (DAC) From Another Agent

From Daily Mod-GRF 1-29 or Sermorelin

Discontinue the short-acting agent. Because mod-GRF 1-29 and sermorelin clear within hours, no formal washout is needed from a PK standpoint. However, a 48-hour break before the first CJC-1295 (DAC) injection allows the pituitary's GHRH-R density to partially re-express, which may improve initial response.

Start CJC-1295 (DAC) at 1 mg subcutaneously once weekly for the first 4 weeks, then titrate to 2 mg weekly if IGF-1 at week 4 remains below the mid-range for age and sex. Do not co-administer a GHRP during the first 2 weeks if the patient was previously on a combined GHRH/GHRP stack; re-introduce ipamorelin at week 3 to avoid an IGF-1 spike.

From Tesamorelin

Tesamorelin's half-life (~26 min) means the last daily dose clears within 4 to 6 hours. A 24-hour break before the first CJC-1295 (DAC) dose is sufficient. If the patient was on tesamorelin for HIV lipodystrophy, confirm that the indication for switching is documented, because payer coverage and compounding-pharmacy access depend on clinical notes.

Start CJC-1295 (DAC) at 1 mg weekly. Monitor IGF-1 at 4 and 8 weeks.

From MK-677

MK-677's half-life is roughly 24 hours, but its functional GH-stimulating effects last the full 24-hour dosing interval. A 72-hour (3-day) washout is appropriate before starting CJC-1295 (DAC), as two different receptor pathways (GHS-R1a and GHRHR) will now both be active once CJC-1295 is introduced, and initial IGF-1 overshoot is a real risk.

Start CJC-1295 (DAC) at 1 mg weekly. Hold MK-677 for the first 4 weeks. Re-introduce MK-677 at 10 mg nightly only if IGF-1 at week 4 is in the lower half of the reference range and the prescribing clinician documents a clear rationale for the combination.

Monitoring Parameters During Any Switch

IGF-1 Targets

The Endocrine Society's 2019 clinical practice guideline on GH deficiency in adults states: "We suggest targeting an IGF-1 concentration in the normal range for age and sex, generally the mid-normal range." [8] For most adults aged 30 to 60, this translates to approximately 150 to 300 ng/mL, though specific reference intervals vary by assay and laboratory.

During a switching window, check IGF-1:

• At baseline (final week of outgoing agent)
• At week 4 of new agent
• At week 12 of new agent (steady state for DAC)
• Every 6 months once stable

Glucose and Insulin Sensitivity

All GH secretagogues can raise fasting glucose through the counter-regulatory effects of GH on insulin sensitivity. This risk is highest with MK-677 [7] and lowest with short-acting GHRH analogs given at bedtime, when GH's insulin-antagonizing effects are partially offset by overnight fasting. Check fasting glucose and HbA1c at baseline and at 12 weeks for any new protocol that includes MK-677 or CJC-1295 (DAC) above 1 mg/week.

Fluid Retention Markers

GH excess classically causes sodium and water retention. During the first 4 weeks after starting CJC-1295 (DAC) at 2 mg weekly, track body weight, blood pressure, and patient-reported edema or paresthesias. A blood pressure rise of more than 10 mmHg systolic from baseline should prompt a dose reduction to 1 mg weekly before further evaluation.

Pituitary Integrity

One under-discussed concern: supraphysiologic, sustained GHRH-R stimulation from the DAC variant has not been studied at the pituitary-adenoma level in long-term human trials. Teichman et al. Followed subjects for only 28 days post-injection. [1] Until longer-term safety data exist, MRI surveillance is reasonable for patients on CJC-1295 (DAC) beyond 12 months, consistent with standard pituitary-function monitoring guidelines from the Endocrine Society. [8]

Practical Dosing Reference for Switches

The table below summarizes the washout and starting-dose guidance from the sections above.

| Outgoing Agent | Incoming Agent | Minimum Washout | Starting Dose (Incoming) | First IGF-1 Check | |---|---|---|---|---| | CJC-1295 (DAC) | Mod-GRF 1-29 + Ipamorelin | 14 days | 100 to 200 mcg each, nightly | Week 4 | | CJC-1295 (DAC) | Sermorelin | 14 days | 200 mcg SC at bedtime | Week 4 | | CJC-1295 (DAC) | Tesamorelin | 14 days | 2 mg SC daily (FDA label) | Week 4 | | CJC-1295 (DAC) | MK-677 | 14 days | 10 mg PO at bedtime | Week 4 | | Mod-GRF 1-29 | CJC-1295 (DAC) | 48 hours | 1 mg SC weekly x 4 weeks | Week 4 | | Sermorelin | CJC-1295 (DAC) | 48 hours | 1 mg SC weekly x 4 weeks | Week 4 | | Tesamorelin | CJC-1295 (DAC) | 24 hours | 1 mg SC weekly x 4 weeks | Week 4 | | MK-677 | CJC-1295 (DAC) | 72 hours | 1 mg SC weekly x 4 weeks | Week 4 |

Special Populations and Contraindications

Active Malignancy

The Endocrine Society guideline explicitly states: "GH treatment is contraindicated in patients with active malignancy." [8] Because CJC-1295 and all GH secretagogues act upstream of GH, the same contraindication applies. Do not initiate any switching protocol in a patient with an active solid tumor or hematologic malignancy.

Diabetes or Pre-Diabetes

Patients with fasting glucose above 100 mg/dL or HbA1c above 5.7% require glucose monitoring every 4 weeks for the first 3 months of any GH secretagogue protocol. The risk is highest with the DAC variant because of its prolonged GH elevation. Consider starting at 0.5 mg weekly in pre-diabetic patients and titrating only after confirming glucose stability.

Hypothyroidism

GH itself increases conversion of thyroxine (T4) to reverse T3. Patients with subclinical or overt hypothyroidism may see thyroid function worsen after GH optimization. Check TSH and free T4 at baseline and at 12 weeks of any new GH secretagogue protocol. This is consistent with monitoring guidance in the 2019 Endocrine Society GH deficiency guidelines. [8]

Compounding and Regulatory Status

CJC-1295 (DAC) and mod-GRF 1-29 are not FDA-approved drugs. They are available through 503A compounding pharmacies under a valid prescription from a licensed prescriber. The FDA does not recognize these peptides as components of approved drug products, which has regulatory implications: in 2023 and 2024, FDA guidance placed several peptides including ipamorelin and sermorelin on the list of substances that may not be compounded under section 503A of the FD&C Act, citing safety and effectiveness concerns. [9]

Prescribers must verify current compounding-pharmacy compliance status before writing any prescription for these agents. The FDA's guidance documents are updated periodically and are available directly at FDA.gov. [9]